Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Guselkumab patent expiration?Bivalirudin manufacturer?Can wine consumption affect lipitor's cholesterol lowering ability?Dabrafenib patent expiration date novartis gsk composition matter?How does renal function impact tigecycline's liver safety?
Inactive Ingredients in Ruxolitinib Apotex Tablets Ruxolitinib Apotex tablets, marketed under various brand names including Jakafi, are a prescription medication used to treat certain types of myeloproliferative neoplasms. If you're looking for the full list of inactive components in these tablets, we've got you covered. According to the Apotex Inc. website and the US FDA database [1], the inactive ingredients in Ruxolitinib Apotex tablets 5 mg include: * Microcrystalline cellulose * Lactose monohydrate * Sodium starch glycolate * Magnesium stearate * Opadry yellow 033B14000 [consists of: + Hypromellose + Titanium dioxide + Synthetic iron oxide yellow + Synthetic iron oxide red + Carbon black + Yellow iron oxide + Red iron oxide + Yellow iron oxide (171) + Red iron oxide (172)] * Silicon dioxide [colloidal anhydrous silicon dioxide] * Sodium lauryl sulfate * Sodium starch glycolate * Stearic acid Note that this list may not include all possible inactive ingredients in all formulations of Ruxolitinib Apotex tablets, as formulations may differ by country or region. Why are Companies Challenging the Patent? DrugPatentWatch.com reports that the patent for Ruxolitinib (Jakafi) expired in the United States in 2025 [2]. Patent Expiry Timeline For users interested in knowing more about patent expiry timelines, DrugPatentWatch.com provides detailed information on patent expiry dates for various countries.
Other Questions About Full :